{"id":760184,"date":"2023-05-24T07:03:27","date_gmt":"2023-05-24T11:03:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/exscientia-business-update-for-first-quarter-2023\/"},"modified":"2023-05-24T07:03:27","modified_gmt":"2023-05-24T11:03:27","slug":"exscientia-business-update-for-first-quarter-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/exscientia-business-update-for-first-quarter-2023\/","title":{"rendered":"Exscientia Business Update for First Quarter 2023"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwalignr { text-align: right; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwleftsingle { border-left: solid black 1pt }\n.bwlistcircle { list-style-type: circle }\n.bwlistdisc { list-style-type: disc }\n.bwpadl1 { padding-left: 5px }\n.bwpadr0 { padding-right: 0px }\n.bwrightsingle { border-right: solid black 1pt }\n.bwrowaltcolor0 { background-color: #cceeff }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwtopsingle { border-top: solid black 1pt }\n.bwvertalignb { vertical-align: bottom }\n.bwvertalignm { vertical-align: middle }\n.bwvertalignt { vertical-align: top }\n.bwwidth1 { width: 1% }\n.bwwidth19 { width: 19% }\n.bwwidth60 { width: 60% }\n.bwwidth75 { width: 75% }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Exscientia Business Update for First Quarter 2023<\/b><\/p>\n<p>OXFORD, England&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nExscientia plc (Nasdaq: EXAI)<\/p>\n<p>\nRecent advancements in the Company\u2019s pipeline, collaborations and operations, as well as financial results for the first quarter 2023, are summarised below. Exscientia will host a <b>conference call Wednesday, May 24 at 1:30 p.m. BST \/ 8:30 a.m. EDT.<\/b><\/p>\n<p>\n\u201cWith our sixth AI-designed compound reaching the clinical development stage plus two more in active IND\/CTA-enabling studies, Exscientia\u2019s pipeline of wholly owned and partnered drug candidates is progressing rapidly,\u201d said Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive Officer of Exscientia. \u201cMost recently, the first patient has been dosed in our IGNITE Phase 1\/2 clinical trial. While many people are familiar with Exscientia\u2019s industry leading drug design capabilities, we also continue to clinically validate our novel, AI-enabled biomarker strategy to ensure that the right patients can benefit from precision medicines in the future.\u201d<\/p>\n<p><b>Recent Highlights<\/b><\/p>\n<p><b>Internal pipeline<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn May 2023, the first patient was dosed in the Phase 1\/2 IGNITE clinical trial of EXS21546 (\u2018546), Exscientia&#8217;s A<sub>2A<\/sub>R antagonist, for the treatment of relapsed\/refractory renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC)<\/p>\n<\/li>\n<li>\nIn April 2023, Exscientia presented four posters at the AACR Annual Meeting highlighting Exscientia\u2019s ability to precision design molecules coupled with the development of multi-gene signatures. The clinical and preclinical data highlighted two programmes, \u2018546 and EXS74539 (\u2018539)<\/p>\n<\/li>\n<li>\nIn March 2023, Exscientia announced two new wholly-owned precision designed molecules, \u2018539, an LSD1 inhibitor, and EXS73565 (&#8216;565), a MALT1 inhibitor<\/p>\n<ul class=\"bwlistcircle\">\n<li>\n\u2018539 and \u2018565 continue to progress through IND\/CTA-enabling studies and Exscientia expects to provide an update on clinical development plans in the second half of 2023<\/p>\n<\/li>\n<li>\nCompany remains on track to meet target of four candidates in clinical development by 2024 (not including Sumitomo Pharma programmes)<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><b>Partnered programmes<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn May 2023, Exscientia announced that DSP-2342, the third compound from the collaboration with Sumitomo Pharma, will enter Phase 1 clinical trials. It is the third molecule created utilising Exscientia\u2019s AI-driven drug discovery platform under a design-as-a-service (DaaS) collaboration with Sumitomo Pharma. The collaboration is now complete and Exscientia retains no economics<\/p>\n<\/li>\n<li>\nIn February 2023, Exscientia announced the initiation of a first-in-human study of EXS4318 (\u20184318), the first immunology &amp; inflammation candidate designed by Exscientia and in-licensed by Bristol Myers Squibb<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nThe potentially first-in-class potent and selective PKC-theta inhibitor is currently in Phase 1 clinical trials in the United States<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><b>Collaboration with Charit\u00e9<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn March 2023, Exscientia announced a collaboration with leading European medical centre Universit\u00e4tsmedizin Berlin (Charit\u00e9) to further validate Exscientia\u2019s precision medicine platform to predict response in haematological cancers<\/p>\n<\/li>\n<li>\nCharit\u00e9 will also establish a biobank of viably cryopreserved blood, bone marrow and lymph node tissues to support further technology development and preclinical research projects at both Exscientia and Charit\u00e9<\/p>\n<\/li>\n<\/ul>\n<p><b>AI and automation highlighted at SLAS 2023<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn May 2023, Exscientia announced the presentation of an oral and poster presentation and the closing keynote for the Society for Laboratory Automation and Screening (SLAS) Europe Conference and Exhibition held in Brussels, Belgium taking place from May 22-May 25. The presentations highlight Exscientia&#8217;s leadership in AI-enabled drug discovery, including advancements in automation<\/p>\n<\/li>\n<\/ul>\n<p><b>Investor Call and Webcast Information<\/b><\/p>\n<p>\nExscientia will host a conference call on Wednesday, May 24 at 1:30 p.m. BST \/ 8:30 a.m. ET. A webcast of the live call can be accessed by visiting the \u201cInvestors and Media\u201d section of the Company\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.exscientia.ai%2F&amp;esheet=53405858&amp;newsitemid=20230524005210&amp;lan=en-US&amp;anchor=investors.exscientia.ai&amp;index=1&amp;md5=6e1224fe9ee7c87a270eec984195a4a0\">investors.exscientia.ai<\/a>. Alternatively, the live conference call can be accessed by dialling +1 (888) 330 3292 (U.S.), +44 203 433 3846 (U.K.), +1 (646) 960 0857 (International) and entering the conference ID: 8333895. A replay will be available for 90 days under &#8220;Events and Presentations\u201d in the \u201cInvestors and Media\u201d section of the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.exscientia.ai%2F&amp;esheet=53405858&amp;newsitemid=20230524005210&amp;lan=en-US&amp;anchor=Exscientia+website&amp;index=2&amp;md5=50a38ff17ca21d00f9182beb6422cfd6\">Exscientia website<\/a>.<\/p>\n<p><b>First Quarter 2023 Financial Results<\/b><\/p>\n<p>\nFor the convenience of the reader, the Company has translated pound sterling amounts to U.S. dollars at the rate of \u00a31.000 to $1.2369, which was the noon buying rate of the Federal Reserve Bank of New York on March 31, 2023.<\/p>\n<p><b>Revenue:<\/b> Revenue for the first quarter 2023 was $7.1 million, compared to $8.6 million for the three months ended March 31, 2022.<\/p>\n<p><b>Research and development expenses: <\/b>R&amp;D expenses for the three months ended March 31, 2023 were $41.3 million, as compared to $28.9 million for the three months ended March 31, 2022. The increase in research and development expenses was in part due to the growth of our internal and co-owned portfolio, increased headcount and increased depreciation charges arising from continued investment into laboratory equipment.<\/p>\n<p><b>General and administrative expenses: <\/b>G&amp;A expenses for the three months ended March 31, 2023, were $13.5 million, or 20.7% of total operating expenses. For the first quarter 2023, G&amp;A expenses increased by $3.8 million compared to the first quarter 2022, primarily associated with an increase in personnel costs associated with growth in headcount.<\/p>\n<p><b>Cash inflows: <\/b>For the first quarter 2023, Exscientia received $0.5 million in cash inflows from its collaborations as compared to $6.3 million during the first quarter 2022.<\/p>\n<p><b>Net operating cash flow and cash balance:<\/b> For the three months ended March 31, 2023, net operating cash outflows were $53.7 million, in comparison to net operating cash outflows of $19.4 million for the three months ended March 31, 2022, reflecting increased research and development spend as well as working capital outflows. Cash, cash equivalents and short term bank deposits as of March 31, 2023 were $553.3 million, as compared to $625.6 million as of December 31, 2022 using the March 31, 2023 constant currency rate.<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIncludes constant currency mark-to-market foreign exchange impact of -2% based on the strengthening of pounds sterling through March 31, 2023<\/p>\n<\/li>\n<li>\nDuring the first quarter of 2023, Exscientia recognised net foreign exchange losses of $1.5 million<\/p>\n<\/li>\n<li>\nThe Company holds its deposits in both GBP and USD, intended to match expected operational cash needs in order to limit the impact of exchange rate fluctuations<\/p>\n<\/li>\n<\/ul>\n<p><b>SELECTED CONSOLIDATED STATEMENT OF OPERATIONS, CONSTANT CURRENCY CONVERSION (unaudited)<br \/>\n<br \/><\/b><i>($ millions, except per share data, at the rate of \u00a31.000 to $1.2369)<\/i><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth75\">\n<tr>\n<td class=\"bwvertalignb bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td colspan=\"3\" class=\"bwvertalignb bwtopsingle bwsinglebottom bwalignc bwpadl1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>Three months ended March 31,<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwpadr0 bwalignc bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>2023<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwpadr0 bwalignc bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>2022<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwrowaltcolor0 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Revenue<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>7.1<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwrowaltcolor0 bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>8.6<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwrowaltcolor0 bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nCost of sales<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(10.5)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(7.0)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwrowaltcolor0 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nResearch and development expenses<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(41.3)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwrowaltcolor0 bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(28.9)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwrowaltcolor0 bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nGeneral and administrative expenses<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(13.5)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(9.7)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwrowaltcolor0 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Operating expenses<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>(65.3)<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwrowaltcolor0 bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>(45.6)<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwrowaltcolor0 bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nForeign exchange (losses)\/gains<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(1.5)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n12.0<\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwrowaltcolor0 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nOther income<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3.2<\/p>\n<\/td>\n<td class=\"bwrightsingle bwrowaltcolor0 bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1.8<\/p>\n<\/td>\n<td class=\"bwrightsingle bwrowaltcolor0 bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Operating loss<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>(56.5)<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>(23.2)<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwrowaltcolor0 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nFinance income\/(expense)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n4.1<\/p>\n<\/td>\n<td class=\"bwrightsingle bwrowaltcolor0 bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(0.0)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwrowaltcolor0 bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nShare of loss on joint ventures<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(0.5)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(0.3)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwrowaltcolor0 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Loss before taxation<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>(52.9)<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwrowaltcolor0 bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>(23.5)<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwrowaltcolor0 bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nIncome tax benefit<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n6.3<\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n4.4<\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwrowaltcolor0 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Loss for the period<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>(46.6)<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwrowaltcolor0 bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>(19.1)<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwrowaltcolor0 bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Net loss per share<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>(0.38)<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>(0.16)<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwrowaltcolor0 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Weighted average shares outstanding<br \/>\n<br \/>(basic and diluted)<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwpadl1 bwvertalignm bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>123,257,529<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwrowaltcolor0 bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwpadl1 bwvertalignm bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>120,959,726<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwrowaltcolor0 bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p><b>SELECTED CONSOLIDATED BALANCE SHEET, CONSTANT CURRENCY CONVERSION (unaudited)<br \/>\n<br \/><\/b><i>($ millions, except per share data, at the rate of \u00a31.000 to $1.2369)<\/i><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth75\">\n<tr>\n<td class=\"bwvertalignb bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignb bwtopsingle bwsinglebottom bwpadl1 bwwidth19 bwpadr0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>March 31, 2023<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwtopsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignb bwtopsingle bwsinglebottom bwpadl1 bwwidth19 bwpadr0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>December 31, 2022<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwtopsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwrowaltcolor0 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nCash, cash equivalents and short term deposits<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignt bwalignr bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n553.4<\/p>\n<\/td>\n<td class=\"bwtablemarginb bwblockalignl bwrowaltcolor0 bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n625.6<\/p>\n<\/td>\n<td class=\"bwtablemarginb bwblockalignl bwrowaltcolor0 bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Total assets<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignt bwalignr bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\"><b>746.2<\/b><\/p>\n<\/td>\n<td class=\"bwtablemarginb bwblockalignl bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>803.5<\/b><\/p>\n<\/td>\n<td class=\"bwtablemarginb bwblockalignl bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwrowaltcolor0 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nTotal equity<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignt bwalignr bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n553.8<\/p>\n<\/td>\n<td class=\"bwtablemarginb bwblockalignl bwrowaltcolor0 bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n592.3<\/p>\n<\/td>\n<td class=\"bwtablemarginb bwblockalignl bwrowaltcolor0 bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nTotal liabilities<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignt bwalignr bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n192.4<\/p>\n<\/td>\n<td class=\"bwtablemarginb bwblockalignl bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n211.2<\/p>\n<\/td>\n<td class=\"bwtablemarginb bwblockalignl bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwrowaltcolor0 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Total equity and liabilities<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignt bwalignr bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\"><b>746.2<\/b><\/p>\n<\/td>\n<td class=\"bwtablemarginb bwblockalignl bwrowaltcolor0 bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwrowaltcolor0 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>803.5<\/b><\/p>\n<\/td>\n<td class=\"bwtablemarginb bwblockalignl bwrowaltcolor0 bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p><b>SELECTED CONSOLIDATED STATEMENT OF CASH FLOWS. CONSTANT CURRENCY CONVERSION (unaudited)<br \/>\n<br \/><\/b>(<i>$ millions, except per share data, at the rate of \u00a31.000 to $1.2369)<\/i><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth75\">\n<tr>\n<td class=\"bwvertalignb bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignb bwtopsingle bwsinglebottom bwpadl1 bwwidth19 bwpadr0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>March 31, 2023<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwtopsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignb bwtopsingle bwsinglebottom bwpadl1 bwwidth19 bwpadr0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>March 31, 2022<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwtopsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth60 bwrowaltcolor0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet cash outflows from operating activities<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19 bwrowaltcolor0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(53.7)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1 bwrowaltcolor0\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19 bwrowaltcolor0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(19.4)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1 bwrowaltcolor0\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet cash flows used in investing activities<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(202.1)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(5.3)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth60 bwrowaltcolor0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet cash used in financing activities<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19 bwrowaltcolor0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(0.9)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1 bwrowaltcolor0\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19 bwrowaltcolor0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(3.3)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1 bwrowaltcolor0\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Net decrease in cash and cash equivalents<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>(256.7)<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>(28.0)<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth60 bwrowaltcolor0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Exchange (loss)\/gain on cash and cash equivalents<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19 bwrowaltcolor0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>(2.0)<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1 bwrowaltcolor0\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadl1 bwwidth19 bwrowaltcolor0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>9.6<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1 bwrowaltcolor0\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth60\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Net decrease in cash, cash equivalents and short-term bank deposits*<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwpadl1 bwwidth19 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>(72.3)<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwpadl1 bwwidth19 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\"><b>(18.4)<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwwidth1\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n* Includes both increases in short term bank deposits and foreign exchange gains\/(losses) on cash and cash equivalents<\/p>\n<p><b>About Exscientia<\/b><\/p>\n<p>\nExscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.<\/p>\n<p>\nFor more information visit us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.exscientia.ai%2F&amp;esheet=53405858&amp;newsitemid=20230524005210&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.exscientia.ai&amp;index=3&amp;md5=84e8633dcd53c0212f04b81c2418c6f3\">https:\/\/www.exscientia.ai<\/a> or follow us on Twitter <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fexscientiaai&amp;esheet=53405858&amp;newsitemid=20230524005210&amp;lan=en-US&amp;anchor=%40exscientiaAI&amp;index=4&amp;md5=26055f41377679fbc5f45ffbbbf66192\">@exscientiaAI<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to: the progress of discovery and development of candidate molecules; the timing and progress of, and data reported from, clinical trials of Exscientia\u2019s product candidates; and the progress and outcome of Exscientia\u2019s collaboration with Charit\u00e9. Any statement describing Exscientia\u2019s goals, plans, expectations, projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to: the initiation, scope and progress of Exscientia\u2019s and its partners\u2019 planned and ongoing pre-clinical studies and clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; Charit\u00e9\u2019s actions under the collaboration agreement, including with respect to establishing a biobank of cryopreserved tissues; the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics; and the endeavour of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia\u2019s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings that Exscientia makes with the SEC from time to time (which are available at<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sec.gov%2F&amp;esheet=53405858&amp;newsitemid=20230524005210&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.sec.gov%2F&amp;index=5&amp;md5=63b1dcc437e883feef83516f22ea4de5\"> https:\/\/www.sec.gov\/<\/a>), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia\u2019s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia\u2019s forward-looking statements reflect the good faith judgement of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230524005210r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230524005210\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230524005210\/en\/<\/a><\/span><\/p>\n<p><b>Investor Relations:<br \/>\n<\/b><br \/>Sara Sherman<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@exscientia.ai\">investors@exscientia.ai<br \/>\n<\/a><\/p>\n<p><b>Media:<br \/>\n<\/b><br \/>Oliver Stohlmann<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:media@exscientia.ai\">media@exscientia.ai<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United Kingdom Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Technology Research Health Technology Biotechnology Health Pharmaceutical Science Artificial Intelligence Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230524005210\/en\/1801576\/3\/Exscientia_logo-01.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Exscientia Business Update for First Quarter 2023 OXFORD, England&#8211;(BUSINESS WIRE)&#8211; Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company\u2019s pipeline, collaborations and operations, as well as financial results for the first quarter 2023, are summarised below. Exscientia will host a conference call Wednesday, May 24 at 1:30 p.m. BST \/ 8:30 a.m. EDT. \u201cWith our sixth AI-designed compound reaching the clinical development stage plus two more in active IND\/CTA-enabling studies, Exscientia\u2019s pipeline of wholly owned and partnered drug candidates is progressing rapidly,\u201d said Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive Officer of Exscientia. \u201cMost recently, the first patient has been dosed in our IGNITE Phase 1\/2 clinical trial. While many people are familiar with Exscientia\u2019s industry leading drug &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exscientia-business-update-for-first-quarter-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Exscientia Business Update for First Quarter 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-760184","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Exscientia Business Update for First Quarter 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exscientia-business-update-for-first-quarter-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exscientia Business Update for First Quarter 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Exscientia Business Update for First Quarter 2023 OXFORD, England&#8211;(BUSINESS WIRE)&#8211; Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company\u2019s pipeline, collaborations and operations, as well as financial results for the first quarter 2023, are summarised below. Exscientia will host a conference call Wednesday, May 24 at 1:30 p.m. BST \/ 8:30 a.m. EDT. \u201cWith our sixth AI-designed compound reaching the clinical development stage plus two more in active IND\/CTA-enabling studies, Exscientia\u2019s pipeline of wholly owned and partnered drug candidates is progressing rapidly,\u201d said Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive Officer of Exscientia. \u201cMost recently, the first patient has been dosed in our IGNITE Phase 1\/2 clinical trial. While many people are familiar with Exscientia\u2019s industry leading drug &hellip; Continue reading &quot;Exscientia Business Update for First Quarter 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/exscientia-business-update-for-first-quarter-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-24T11:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230524005210r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exscientia-business-update-for-first-quarter-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exscientia-business-update-for-first-quarter-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Exscientia Business Update for First Quarter 2023\",\"datePublished\":\"2023-05-24T11:03:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exscientia-business-update-for-first-quarter-2023\\\/\"},\"wordCount\":1592,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exscientia-business-update-for-first-quarter-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230524005210r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exscientia-business-update-for-first-quarter-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exscientia-business-update-for-first-quarter-2023\\\/\",\"name\":\"Exscientia Business Update for First Quarter 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exscientia-business-update-for-first-quarter-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exscientia-business-update-for-first-quarter-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230524005210r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-05-24T11:03:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exscientia-business-update-for-first-quarter-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exscientia-business-update-for-first-quarter-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exscientia-business-update-for-first-quarter-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230524005210r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230524005210r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exscientia-business-update-for-first-quarter-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exscientia Business Update for First Quarter 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exscientia Business Update for First Quarter 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/exscientia-business-update-for-first-quarter-2023\/","og_locale":"en_US","og_type":"article","og_title":"Exscientia Business Update for First Quarter 2023 - Market Newsdesk","og_description":"Exscientia Business Update for First Quarter 2023 OXFORD, England&#8211;(BUSINESS WIRE)&#8211; Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company\u2019s pipeline, collaborations and operations, as well as financial results for the first quarter 2023, are summarised below. Exscientia will host a conference call Wednesday, May 24 at 1:30 p.m. BST \/ 8:30 a.m. EDT. \u201cWith our sixth AI-designed compound reaching the clinical development stage plus two more in active IND\/CTA-enabling studies, Exscientia\u2019s pipeline of wholly owned and partnered drug candidates is progressing rapidly,\u201d said Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive Officer of Exscientia. \u201cMost recently, the first patient has been dosed in our IGNITE Phase 1\/2 clinical trial. While many people are familiar with Exscientia\u2019s industry leading drug &hellip; Continue reading \"Exscientia Business Update for First Quarter 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/exscientia-business-update-for-first-quarter-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-24T11:03:27+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230524005210r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exscientia-business-update-for-first-quarter-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exscientia-business-update-for-first-quarter-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Exscientia Business Update for First Quarter 2023","datePublished":"2023-05-24T11:03:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exscientia-business-update-for-first-quarter-2023\/"},"wordCount":1592,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exscientia-business-update-for-first-quarter-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230524005210r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exscientia-business-update-for-first-quarter-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/exscientia-business-update-for-first-quarter-2023\/","name":"Exscientia Business Update for First Quarter 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exscientia-business-update-for-first-quarter-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exscientia-business-update-for-first-quarter-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230524005210r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-05-24T11:03:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exscientia-business-update-for-first-quarter-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/exscientia-business-update-for-first-quarter-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exscientia-business-update-for-first-quarter-2023\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230524005210r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230524005210r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exscientia-business-update-for-first-quarter-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Exscientia Business Update for First Quarter 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/760184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=760184"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/760184\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=760184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=760184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=760184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}